205
Views
28
CrossRef citations to date
0
Altmetric
Research Article

In AML Cell Lines Ara-C Combined with Purine Analogues is Able to Exert Synergistic as Well as Antagonistic Effects on Proliferation, Apoptosis and Disruption of Mitochondrial Membrane Potential

, , , , , , & show all
Pages 165-173 | Published online: 01 Jul 2009

  • Cheson, B.D. (1992) "New antimetabolites in the treatment of human malignancies", Semin. Oncol. 19, 695-706.
  • Galmarini, C.M., Mackey, J.R. and Dumontet, C. (2001) "Nucleoside analogues: mechanisms of drug resistance and reversal strategies". Leukenmia 15, 875-890.
  • Gandhi, V., Estey, E., Keating, M.J. and Plunkett, W. (1993) "Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy", J. Clin. Oncol. 11. 116-124.
  • Gandhi, V. and Plunkett, W. (1988) "Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells", Cancer Res. 48, 329-334.
  • Gandhi, V., Estey, E., Keating, M.J., Chucrallah, A. and Plunkett, W. (1996) "Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemai: pharmacokinetic, pharmacodynamic. and molecular interactions". Blood 87. 256-264.
  • Gandhi, V., Estey, E., Keating, M.J. and Plunkett, W. (1993) "Biochemical modulation of arabinosylcytosine for therapy of leukemias", Leuk. Lymphoma 10(Suppl.), 109-114.
  • Plunkett, W. and Gandhi, V. (2001) "Purine and pyrimidine nucleoside analogs", Cancer Chemother. Biol. Response Modif. 19, 21-45.
  • Carson, D.A., Wasson, D.B., Taetle, R. and Yu, A. (1983) "Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes", Blood 62, 737-743.
  • Plunkett, W. and Gandhi, V. (1996) "Pharmacology of purine nucleoside analogues", Hematol. Cell Ther. 38(Suppl. 2), S67-S74.
  • Gandhi, V. and Plunkett, W. (2002) "Cellular and clinical pharamacology of fludarabine", Clin. Phamacokinet. 41, 93-103.
  • Schwaenen, C., Karakas, T. and Bergmann, L. (2002) "Bendamustine in the treatment of low-grad Non-Hodgkin's Iymphomas", Onkologie 23, 318-324.
  • Kath, R., Blumenstengel, K., Fricke, H.J. and Hoffken, K. (2001) "Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia", J. Cancer Res. Clin. Oncol. 127, 48-54.
  • Kroemer, G. and Reed, J.C. (2000) "Mitochondrial control of cell death", Nat. Med, 6, 513-519.
  • Reed, J.C., Jurgensmeier, J.M. and Matsuyama, S. (1998) "Bel-2 family proteins and mitochondria", Biochim. Biophys. Acta 1366, 127-137.
  • Boehere, S., Chow. K.U., Beske, F., Kukoc-Zivojnov, N., Pucetti, E., Ruthardt, M., et al. (2002) "In lymphatic cells Par-4 sensitizes at apoptosis by down-regulating Bcl-2 and promoting disruption of mitochondrial membrane potential and caspase activation", Cancer Res. 62, 1768-1775.
  • Reed, J.C. (1999) "Dysregulation of apoptosis in cancer", J. Clin. Oncol. 17, 2941-2953.
  • Chow, K.U., Boehrer, S., Geduldig, K., Kraphol, A., Hoelzer, D., Mitrou, P.S., et al. (2001) "In vitro induction of apoptosis in neoplastic cells in low-grade non-Hodgkin's lymphomas (NHL) using combinations of established cytotoxic drugs with bendamustine", Haematololgica 86, 485-493.
  • Reers, M., Smiley, S.T., Mottola-Hartshorn, C., Chen, A., Lin, M. and Chen, L.B. (1995) "Mitochondrial membrane potential monitored by JC-1 dye", Methods Enzymol. 260, 406-417.
  • Salvioli, S., Ardizzoni, A., Franceschi, C. and Cossarizza, A. (1997) "JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: implications for studies on mitochondrial functionality during apoptosis". FEBS Lett. 411, 77-82.
  • Chou, T.C. (1994) "Assessment of synergistic and antagonistic effects of chemotherapeutic agents in vitro", Contrib. Gynecol. Obstet. 19, 91-107.
  • Chou, T.C., Motzer, R.J., Tong, Y. and Bosl, G.J. (1994) "Computerized quantitation of synergims and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design", J. Natl Cancer Inst. 86, 1517-1524.
  • Debatin, K.M. (1999) "Activation of apoptosis pathways by anticancer drugs", Adv. Exp. Med. Biol. 457, 237-244.
  • Gandhi, V., Kemena, A., Keating, M.J. and Plunkett, W. (1992) "Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia", Cancer Res. 52, 897-903.
  • Kano, Y., Akutsu, M., Tsunoda, S., Suzuki, K., Ichikawa, A., Furukawa, Y., et al. (2000) "In vitro cytotoxic effects of fludarabine (2-Fara-A) in combination with commonly used antileukemic agants by isobologram analysis", Leukemia 14, 379-388.
  • Tosi, P., Visani, G., Ottaviani, E., Manfori, S., Zinzani, P.L. and Tura, S. (1994) "Fludarabine + Ara-C + G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells", Leukemia 8, 2076-2082.
  • Kornablau, S.M., Gandhi, V., Andreeff, H.M., Beran,M., Kantarjian, H.M., Koller. C.A., et al. (1996) "Clinical and laboratory studies of 2-chlorodeoxyadenosine ± cytosine arabmoside for relapsed or refractory acute myelogenous leukemia in adults", Leukemia 10, 1563-1569.
  • Friesen, C., Herr, I., Krammer, P.H. and Debatin, K.M. (1996) "Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells", Nat. Med. 2, 574-577.
  • Chow, K.U., Nowak, D., Boehrer, S., Ruthardt, M., Knau, A., Hoelzer, D. et al. (2002) "In lymphatic cells synergistic effects of apoptosis induced by chemotherapeutic drug combinations are dependent on enhanced cytochrome c-release, enforced caspase activation and concomitant down-regulation of XIAP and cIAPl", Submitted for publication.
  • Achanta, G., Pelicano, H., Feng, L., Plunkett, W. and Huang, P. (2001) "Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage", Cancer Res. 61, 8723-8729.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.